The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The objective of this substudy was to examine the effect of desvenlafaxine 50 mg/day compared with placebo on cognitive function in employed outpatients with major depressive disorder. A total of 11/55 (20%) study sites in a 12-week, randomized, double-blind, placebo-controlled trial administered cognitive assessments in memory, attention, and executive functioning domains using the cognitive drug research system. Changes from baseline were subjected to analysis of covariance with baseline levels as covariates, using last observation carried forward data. A significant improvement with desvenlafaxine 50 mg/day ( n=52) compared with placebo ( n=29) was observed on the quality of working memory composite measure (0.081 units (0.005, 0.156); P=0.0365) at last observation carried forward. Improvement from baseline on the speed of working memory composite was significant for desvenlafaxine (−226.6 msec (−316.7, −136.4); P<0.0001) and for placebo (−133.3 msec (−257.2, −9.4); P=0.0354); however, the treatment effect was not significant. No significant differences between groups were observed on composite measures for attention. Treatment of depression with desvenlafaxine 50 mg/day may improve aspects of cognitive functioning, including working memory. Clinical Trial Registry No.: Clinicaltrials.gov identifier: NCT00824291
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a 12-week, randomized, double-blind, and placebocontrolled trial, desvenlafaxine displayed significant improvement on working memory.”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Studies of interference in serial verbal reactions
Stroop, J. R. (1935) · Journal of Experimental Psychology · doi:10.1037/h0054651 · Cited by 18,622
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Validity of the Trail Making Test as an Indicator of Organic Brain Damage
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 7,928
Cost of Lost Productive Work Time Among US Workers With Depression
Stewart, W. F. (2003) · JAMA · doi:10.1001/jama.289.23.3135 · Cited by 1,421
Handbook of Psychiatric Measures
SALZMAN, C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1343 · Cited by 1,174
Cognitive deficits in depression: Possible implications for functional neuropathology
Austin, M.-P., Mitchell, P., & Goodwin, G. M. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.200 · Cited by 1,154
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
DSM‐IV‐TR: Diagnostic and Statistical Manual of Mental Disorders
Chao, R. C., & Manita, J. (2013) · The Encyclopedia of Cross‐Cultural Psychology · doi:10.1002/9781118339893.wbeccp180 · Cited by 683
Adrenergic pharmacology and cognition: Focus on the prefrontal cortex
Ramos, B. P., & Arnsten, A. F. T. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.006 · Cited by 641
Research works printed but not linked: 4
- Clayton A, 2014, J Clin Psychiatry
- Frodl T, 2006, J Psychiatry Neurosci, 31, 316
- Greer TL, 2014, Depress Res Treat, 2014, 627863
- Wagner G, 2008, J Psychiatry Neurosci, 33, 199
Cited by
Restoring function in major depressive disorder: A systematic review
Sheehan, D. V., Nakagome, K., Asami, Y., Pappadopulos, E. A., & Boucher, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.029 · Cited by 182
Cognitive dysfunction in major depression: From assessment to novel therapies
Atique-Ur-Rehman, H., & Neill, J. C. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.013 · Cited by 72
“, 2016 used the cognitive drug research (CDR) system to show significant working memory improvements over 12 weeks (Reddy et al., 2016).”
BackgroundSalagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71
Ahern, E., White, J., & Slattery, E. J. (2024) · Neuropsychology Review · doi:10.1007/s11065-023-09629-9 · Cited by 50
Effects of antidepressants on QT interval in people with mental disorders
Aronow, W. S., & Shamliyan, T. (2020) · Archives of Medical Science · doi:10.5114/aoms.2019.86928 · Cited by 39
Metadata
- Authors
- Reddy, S., Fayyad, R., Edgar, C. J., Guico-Pabia, C. J., & Wesnes, K.
- Affiliations
- Wyeth (US)
- Pfizer (United States) (US)
- Formerly of Bracket Global, Goring-on-Thames, UK
- Formerly of Pfizer Inc., formerly Wyeth Research, Collegeville, PA, USA
- Northumbria University (GB)
- Corresponding author
- Reddy, Sujana
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-23
- Volume
- 30
- Issue
- 6
- Pages
- 559-567
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2334214451
- Cited by
- 17
- References
- 56
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2022: 2 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 1
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Northumbria Research Link (Northumbria University) (submittedVersion)
- Swinburne figshare (Swinburne University of Technology) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- desvenlafaxine, major depressive disorder, cognitive function, working memory, attention, executive function, norepinephrine reuptake inhibitors
- MeSH terms
- Desvenlafaxine Succinate, Adult, Antidepressive Agents, Cognition, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Outpatients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.